PCN87 PHARMACOECONOMIC ANALYSIS OF DIRECT MEDICAL COSTS OF METASTATIC COLORECTAL CANCER THERAPY WITH XELOX OR FOLFOX4 WITH OR WITHOUT BEVACIZUMAB AS THE FIRST-LINE TREATMENT
Nov 1, 2010, 00:00
10.1016/S1098-3015(11)71982-9
https://www.valueinhealthjournal.com/article/S1098-3015(11)71982-9/fulltext
Title :
PCN87 PHARMACOECONOMIC ANALYSIS OF DIRECT MEDICAL COSTS OF METASTATIC COLORECTAL CANCER THERAPY WITH XELOX OR FOLFOX4 WITH OR WITHOUT BEVACIZUMAB AS THE FIRST-LINE TREATMENT
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)71982-9&doi=10.1016/S1098-3015(11)71982-9
First page :
A267
Section Title :
RESEARCH POSTER ABSTRACTS
Open access? :
No
Section Order :
140